• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, June 26, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Study finds dangerous increases in patients mixing opioids, benzodiazepines or Z-drugs

Bioengineer by Bioengineer
January 17, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The number of Americans taking a dangerous combination of opioids along with drugs commonly prescribed for pain, insomnia and anxiety ‘is alarming,’ says study’s author

The number of Americans taking a dangerous combination of both opioids and benzodiazepines — a group of drugs commonly prescribed for pain, insomnia and anxiety — increased by 250 percent over a 15-year period, while there was an 850 per cent increase in patients taking both benzodiazepines and so-called Z-drugs, which act similarly to benzodiazepines, according to a new study published in the journal Sleep.

The research by Dr. Nicholas Vozoris, an associate scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto, relies on data from eight National Health and Nutrition Examination Survey (NHANES) cycles between 1999 and 2014. It found the prevalence of benzodiazepine and opioid co-usage in the United States in 2014 was 1.36 percent, while the prevalence of benzodiazepine and Z-drug co-usage was 0.47 percent.

Dr. Vozoris found the increases in co-usage very concerning given that these drug-use patterns are associated with increased risks for serious adverse outcomes including breathing problems and death.

“While the proportions may seem small, these percentages at a population-level correspond to millions of people and the growth of these numbers is alarming,” said Dr. Vozoris, a sleep medicine doctor who often sees patients in his clinic who are taking a worrisome or dangerous combination of drugs.

“The FDA has gone as far as to issue its strongest form of safety warning about this suboptimal prescribing practice and mixing of opioids and benzodiazepines.”

The 1.36 percent prevalence of benzodiazepine and opioid co-usage translated to about 4.3 million people, while the 0.47 percent prevalence of benzodiazepine and Z-drug co-usage amounted to about 1.5 million people.

Dr. Vozoris said he’s seen a lot of confusion about benzodiazepines and Z-drugs among both patients and other medical professionals.

Commonly prescribed benzodiazepines include alprazolam, clonazepam and lorazepam while Z-drugs include zaleplon, zolpidem and zopiclone.

“There are doctors and members of the public often not realizing that Z-drugs are very similar in action to benzodiazepine drugs — sometimes patients get put on both a benzo and a Z-drug and think they’re two very different drugs,” Dr. Vozoris said.

“I wanted to understand the trends in use of such worrisome drug combinations and which types of individuals were more likely to receive such drug combinations.”

###

Media Contact
Michael Oliveira
[email protected]
416-864-5047

Tags: AddictionCritical Care/Emergency MedicineDrugsMedicine/HealthPainPharmaceutical SciencePharmaceutical SciencesPublic Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Tracking Lanthanide-Labeled Microplastics in Plants

June 25, 2026

Neural Design Enables Zero-Shot Drug-Binding Proteins

June 25, 2026

Genomic Insights into Human Skin Fungi Diversity

June 25, 2026

Chiral Laser Gyroscopes Surpass Lock-In Limit

June 25, 2026
Please login to join discussion

POPULAR NEWS

  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • Multi-Hospital Study Reveals Long Covid Burden Is Twice as High as Current Estimates

    92 shares
    Share 36 Tweet 23
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tracking Lanthanide-Labeled Microplastics in Plants

POSTECH Researchers Slash Cost of Reconstituted Cell-Free Systems by 95%

AI and Physics Collaborate to Design Advanced Hydrogen Storage Materials

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.